Rapid Micro Biosystems Balance Sheet Health
Financial Health criteria checks 5/6
Rapid Micro Biosystems has a total shareholder equity of $20.4M and total debt of $19.1M, which brings its debt-to-equity ratio to 93.4%. Its total assets and total liabilities are $62.4M and $42.0M respectively.
Key information
93.41%
Debt to equity ratio
US$19.05m
Debt
| Interest coverage ratio | n/a |
| Cash | US$23.72m |
| Equity | US$20.40m |
| Total liabilities | US$41.97m |
| Total assets | US$62.36m |
Recent financial health updates
We Think Rapid Micro Biosystems (NASDAQ:RPID) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. By way of example, Rapid Micro...We're Keeping An Eye On Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Rapid Micro Biosystems...Is Rapid Micro Biosystems (NASDAQ:RPID) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...We're Keeping An Eye On Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Recent updates
Slow Automation Adoption And Partner Execution Risks May Eventually Support QC Automation Upside
Catalysts About Rapid Micro Biosystems Rapid Micro Biosystems provides automated microbial quality control systems and related consumables and services for biopharma and other regulated manufacturing labs. What are the underlying business or industry changes driving this perspective?
Automation And Advanced Biomanufacturing Adoption Will Drive Long Term Value For This QC Leader
Catalysts About Rapid Micro Biosystems Rapid Micro Biosystems provides automated microbial quality control systems and consumables for biopharma and related regulated industries. What are the underlying business or industry changes driving this perspective?Rapid Micro Biosystems: Big Pharma Adoption Driving Growth
Summary Rapid Micro Biosystems, Inc. posted strong FY25 revenue growth, driven by Growth Direct system placements, but remains unprofitable with a $47M net loss. RPID's growth hinges on large multi-system orders from major pharmaceutical manufacturers, with recurring revenue from consumables and services now 53% of total revenue. A premium valuation (6.4x P/S) reflects high expectations for platform adoption, but negative margins and ongoing cash burn temper near-term optimism. I maintain a Hold rating, citing the need for continued system placements, improved profitability, and successful execution of strategic partnerships like MilliporeSigma. Read the full article on Seeking AlphaRapid Micro Biosystems, Inc. (NASDAQ:RPID) Stocks Shoot Up 25% But Its P/S Still Looks Reasonable
Despite an already strong run, Rapid Micro Biosystems, Inc. ( NASDAQ:RPID ) shares have been powering on, with a gain...Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) 37% Jump Shows Its Popularity With Investors
Despite an already strong run, Rapid Micro Biosystems, Inc. ( NASDAQ:RPID ) shares have been powering on, with a gain...We Think Rapid Micro Biosystems (NASDAQ:RPID) Needs To Drive Business Growth Carefully
We can readily understand why investors are attracted to unprofitable companies. By way of example, Rapid Micro...Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Stocks Shoot Up 45% But Its P/S Still Looks Reasonable
Rapid Micro Biosystems, Inc. ( NASDAQ:RPID ) shares have had a really impressive month, gaining 45% after a shaky...We're Keeping An Eye On Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Rapid Micro Biosystems...
MilliporeSigma And Lonza Collaborations Will Expand Market Reach
The global agreement with MilliporeSigma is set to expand Growth Direct's market reach and potentially enhance supply chain efficiency, boosting future revenues.Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Just Reported And Analysts Have Been Lifting Their Price Targets
It's been a mediocre week for Rapid Micro Biosystems, Inc. ( NASDAQ:RPID ) shareholders, with the stock dropping 12% to...Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Looks Just Right With A 70% Price Jump
Rapid Micro Biosystems, Inc. ( NASDAQ:RPID ) shares have continued their recent momentum with a 70% gain in the last...Investors Still Aren't Entirely Convinced By Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) Revenues Despite 27% Price Jump
Despite an already strong run, Rapid Micro Biosystems, Inc. ( NASDAQ:RPID ) shares have been powering on, with a gain...Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) Shares Leap 25% Yet They're Still Not Telling The Full Story
Rapid Micro Biosystems, Inc. ( NASDAQ:RPID ) shares have continued their recent momentum with a 25% gain in the last...Is Rapid Micro Biosystems (NASDAQ:RPID) In A Good Position To Invest In Growth?
Just because a business does not make any money, does not mean that the stock will go down. For example, although...A Piece Of The Puzzle Missing From Rapid Micro Biosystems, Inc.'s (NASDAQ:RPID) 32% Share Price Climb
Rapid Micro Biosystems, Inc. ( NASDAQ:RPID ) shareholders are no doubt pleased to see that the share price has bounced...We're Keeping An Eye On Rapid Micro Biosystems' (NASDAQ:RPID) Cash Burn Rate
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...Rapid Micro to introduce RMBNucleus software for mold detection in pharma manufacturing
Rapid Micro Biosystems (NASDAQ:RPID) said it will introduce a new software, RMBNucleus Mold Alarm to rapidly detect environmental molds in the pharmaceutical manufacturing process. RMBNucleus is expected to be available on the Growth Direct System before the end of 2022, the company said in an Oct. 10 press release. "As with each of our products on the Growth Direct System, RMBNucleus Mold Alarm comes with enhanced data integrity and generates automated alerts at the first sign of mold detection in as little as one day, allowing for early intervention and reduced risk of contamination," said Rapid President and CEO Rob Spignesi.Financial Position Analysis
Short Term Liabilities: RPID's short term assets ($49.2M) exceed its short term liabilities ($19.1M).
Long Term Liabilities: RPID's short term assets ($49.2M) exceed its long term liabilities ($22.8M).
Debt to Equity History and Analysis
Debt Level: RPID has more cash than its total debt.
Reducing Debt: RPID's debt to equity ratio has increased from 25.3% to 93.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RPID has sufficient cash runway for 7 months based on last reported free cash flow, but has since raised additional capital.
Forecast Cash Runway: RPID is forecast to have sufficient cash runway for 7 months based on free cash flow estimates, but has since raised additional capital.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/16 14:47 |
| End of Day Share Price | 2026/06/16 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Rapid Micro Biosystems, Inc. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tycho Peterson | J.P. Morgan |
| Paul Knight | KeyBanc Capital Markets Inc. |
| Thomas Flaten | Lake Street Capital Markets, LLC |